Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P668: Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infectionsECCO '17 Barcelona
Year: 2017
Authors:

Bhayat F.1, Blake A.*2, Travis S.3

1Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom 2Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 3University of Oxford, Translational Gastroenterology Unit, Nuffield Department of Medicine, Oxford, United Kingdom

P669: Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registryECCO '17 Barcelona
Year: 2017
Authors:

Loftus Jr. E.*1, D'Haens G.2, Reinisch W.3, Satsangi J.4, Panaccione R.5, Berg S.6, Alperovich G.7, Bereswill M.8, Kalabic J.8, Skup M.9, Petersson J.9, Robinson A.M.9

1Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 2Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands 3Medical University of Vienna, Vienna, Austria 4Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom 5University of Calgary, Department of Medicine, Calgary, Canada 6AbbVie AB, Solna, Sweden 7AbbVie Spain S.L.U., Madrid, Spain 8AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany 9AbbVie Inc., North Chicago, United States

P670: Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care populationECCO '17 Barcelona
Year: 2017
Authors:

Ahmed R., O'Connell G., Love M., Davis J., Cooney R., Pathmakanthan S., Iqbal T., Bhala N.

Queen Elizabeth Hospital Birmingham, University Hospitals Birmigham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom

P671: Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Mortensen J.H.*1, van Haaften W.T.2,3, Olesen M.L.1,4, Karsdal M.1, Olinga P.2, Dijkstra G.3, Bay-Jensen A.-C.1

1Nordic Bioscience, Biomarkers & Research, Herlev, Denmark 2University Medical Center Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands 3University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands 4University of Southern Denmark and Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark

P672: Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Xu P.-p.*1, Qiu Y.2, Jia Y.-l.1, Xu L.1, He C.-y.1, Han Z.1

1The First Affiliated Hospital of Wannan Medical College, Wuhu, China 2The First Affiliated Hospital of Sun Yat-Sen Medical University, Guangzhou, China

P673: Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapyECCO '17 Barcelona
Year: 2017
Authors:

Subramaniam K.*1,2, Tweedale M.1, Pavli P.1,2

1Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia 2Australian National University, ANU Medical School, Canberra, Australia

P674: Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Kang B.*1, Lee K.1, Choe B.-H.2, Choe Y.H.1

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Kyungpook National University Hospital, Kyungpook National University School of Medicine, Department of Pediatrics, Daegu, South Korea

P675: Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week dataECCO '17 Barcelona
Year: 2017
Authors:

Molnár T.*1, Farkas K.1, Rutka M.1, Ferenci T.2, Nagy F.1, Bálint A.1, Bor R.1, Milassin A.1, Fábián A.1, Végh Z.3, Kürti Z.3, Lakatos P.L.3, Szepes Z.1

1University of Szeged, 1st Department of Medicine, Szeged, Hungary 2John von Neumann Faculty of Informatics of Óbuda University, Budapest, Hungary 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary

P676: Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United StatesECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.*1, Sakuraba A.2, Wang A.3, Macaulay D.4, Schemerold L.4, Yang M.5, Skup M.3

1University of California San Diego, La Jolla, United States 2University of Chicago, Chicago, United States 3AbbVie Inc., North Chicago, United States 4Analysis Group, Inc., New York, United States 5Analysis Group, Inc., Boston, United States

P677: Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Chao C.-Y.*1,2, Lemieux C.1, Afif W.1, Bitton A.1, Wild G.1, Bessissow T.1

1McGill University Health Centre, Department of Gastroenterology, Montréal, Canada 2Princess Alexandra Hospital, Department of Gastroenterology, Brisbane, Australia

P678: Did toxicity profile of azathioprine changed within the last 10 years: comparative 17 years data from a single tertiary IBD centerECCO '17 Barcelona
Year: 2017
Authors:

Bozcan S., Hatemi I., Yıldırım S., Demir N., Erzin Y., Celik A.F.

Istanbul University Cerrahpasa School of Medicine, Gastroenterology, Istanbul, Turkey

P679: Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatmentECCO '17 Barcelona
Year: 2017
Authors:

Gompertz M., Alfaro I., Ricart E., Lόpez A., Panés J., Gallego M., Barastegui R., Giner A., Vara A., Masamunt M., Ordás I.

Hospital Clinic Barcelona, Department of Gastroenterology, Barcelona, Spain

P680: Quality of sex life in patients with inflammatory bowel disease: the gastroenterologists' perspectiveECCO '17 Barcelona
Year: 2017
Authors:

Rivière P., Laharie D., Zerbib F., Poullenot F.

Bordeaux University Hospital, Bordeaux, France

P681: Assessing internet based information used to aid patient decision making in surgery for perianal Crohn's fistulaECCO '17 Barcelona
Year: 2017
Authors:

Marshall J.*1, Baker D.1, Lee M.2, Jones G.3, Lobo A.4, Brown S.2

1University of Sheffield, The Medical School, Sheffield, United Kingdom 2Sheffield Teaching Hospitals, Colorectal Surgery, Sheffield, United Kingdom 3Leeds Beckett University, School of Social Sciences, Leeds, United Kingdom 4Royal Hallamshire Hospital/University of Sheffield, Department of Gastroenterology, Sheffield, United Kingdom

P682: Risk factors and clinical outcome in IBD patients with melanomaECCO '17 Barcelona
Year: 2017
Authors:

Nissen L.H.*1, Pierik M.2, Derikx L.A.A.P.3, de Jong E.4, Kievit W.3, van den Heuvel T.2, van Rosendael A.5, Plasmeijer E.5, Dewint P.6, Nagtegaal I.D.7, Hoentjen F.3, van der Meulen A.5

1Radboud UMC, Gastroenterology & Hepatology, Nijmegen, Netherlands 2Maastricht University Medical Center, Department of Gastroenterology and Hepatology, Maastricht, Netherlands 3Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands 4Radboud University Nijmegen Medical Centre, Dermatology, Nijmegen, Netherlands 5Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, Netherlands 6Maasstad Ziekenhuis, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands 7Radboud University Medical Center, Department of Histopathology, Nijmegen, Netherlands

P683: Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF-α treatmentECCO '17 Barcelona
Year: 2017
Authors:

Borruel N.*1, Guillen M.C.2, Salvador F.3, Herrera C.1, Alcover M.M.2, Sulleiro E.4, Robles V.1, Berenguer D.2, Sánchez-Montalvá A.3, Rodríguez V.1, Tomás-Pérez M.2, Molina I.3, Navarro E.1, Iniesta L.2, Fisa R.2, Riera C.2, Casellas F.1

1Hospital Vall d'Hebron, Crohn's and Colitis attention Unit, Barcelona, Spain 2Universitat de Barcelona. Faculty of Pharmacy and Food Science, Department of Biology, Health and Environement. Laboratory of Parasitology, Barcelona, Spain 3Hospital Vall d'Hebron, Department of Infectious Diseases, Barcelona, Spain 4Hospital Vall d'Hebron, Department of Microbiology, Barcelona, Spain

P684: A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Taylor M.*1, Duggal A.1, Rowley A.1, Foster M.1, Sirohi S.1, Solanke Y.1, Walshe C.1, Webber S.1, Travis S.2, Irving P.3

1Topivert Pharma Ltd, London, United Kingdom 2Oxford University Hospitals Trust, Translational Gastroenterology Unit, Oxford, United Kingdom 3Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P685: Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Huoponen S.*1, Eberl A.1,2, Räsänen P.1,2, Roine R.P.2,3, Sipponen T.1,2, Arkkila P.1,2, Blom M.1

1University of Helsinki, Helsinki, Finland 2Helsinki University Hospital, Helsinki, Finland 3University of Eastern Finland, Kuopio, Finland

P686: Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Detrez I.*1, Ballet V.2, Van Assche G.2, Vermeire S.2, Ferrante M.2, Gils A.1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

P687: Fate of the rectum in anorectal Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Zambonin D., Scaringi S., Di Bella A., Giudici F., Bechi P.

University of Florence, Florence, Italy